Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-133

Thanks Anna,

I think the lads at Taylor's had too many Cognacs when they were writing that update.

Shareholders would be hurling if ANP did a CR in the mid 20's.

That would be a MASSIVE failure of the Board.

Given the quality of P2 results and pivotal nature of P2B....throw in new indications...and the future value of RPDD voucher being more than our current market cap....

How is a CR for EMA in the mid 20's acceptable?

Especially given the amount of money sloshing around the markets at the moment.

Let's get the new indications out in the market...and start the pump ahead of EMA PIP approval.

Any CR should be 40 to 50c.

BUT it appears Taylors haven't been listening to the "non-dilutive" messages from the CEO.

Time will tell, it always does.
.